Back to top

AngioDynamics receives FDA IDE approval for RELIEF feasibility study

AngioDynamics (ANGO) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s Investigational Device Exemption, IDE, a...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AngioDynamics, Inc. (ANGO)